Dr Reddy's launches asthma drug in US market
New Delhi: Dr Reddy's Laboratories Tuesday said it has launched Montelukast Sodium tablets, used for treating asthma and allergies, in the US market after getting approval from the American health regulator.
The company received approval from US Food and Drug Administration for Montelukast Sodium tablets and Montelukast Sodium chewable tablets in strengths ranging from 4 mg to 10 mg, Dr Reddy's Laboratories said in a statement.
Dr Reddy's launched tablets in the US market yesterday, it added. The Hyderabad-based firm's products are generic versions of Merck & Co's Singulair tablets and chewable tablets.
According to IMS Health data, Singulair tablets and chewable tablets brand had sales of about USD 3.6 billion and USD 1.14 billion, respectively, in the US market for the year ended March 2012.
"Dr Reddy's Montelukast Sodium tablets in 10 mg and Montelukast Sodium chewable tablets in 4 mg and 5 mg are available in bottle counts of 30 and 90," the company said.
Shares of Dr Reddy's Laboratories Tuesday closed at Rs 1,657.40 apiece on the BSE, down 0.01 percent from its previous close.